, /PRNewswire/ — In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-effective next generation sequencing (NGS) solutions.
Expanding U.S. manufacturing capabilities in 2024 and beyond
After weathering a year of geopolitical conflict which resulted in the failure of the BIOSECURE Act, which was legislation that targeted individual companies under the guise of genetic data security, Complete Genomics opened two facilities in 2024 as part of its localization strategy, establishing its first U.S. supply chain.
In May, the company inaugurated a 10,115 square foot manufacturing facility at its San Jose, California headquarters, to provide faster delivery times and reliable local supply assurance for North American customers.
Since then, the new San Jose facility has produced DNBSEQ-G99RS* (“G99“) low-to-mid-range throughput sequencers, used for targeted gene and small genome sequencing research, which are for their exceptionally fast run time of 12 hours with preliminary reporting available in …